Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Management also lowered the midpoint ... The Motley Fool Stock Advisor analyst team just identified what they believe are the ...

It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

How the Development Bank of Wales supports tech-driven companies, ranging from start-ups to established businesses ...

Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Our Greenville, South Carolina office did sustain moderate damage, but thanks to our HSE and facilities management team, the ...

The reactions to Donald's Trump's victory across the crypto, currency, and stock markets. Super Micro's woes, and the outlook for a company with no auditor, no annual report and, perhaps soon, no ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...